贝曲沙班（Bevyxxa）：一种直接作用的口服抗凝剂，Xa因子抑制剂。
Betrixaban (Bevyxxa): A Direct-Acting Oral Anticoagulant Factor Xa Inhibitor.
作者信息
Skelley Jessica W, Thomason Angela R, Nolen Jeffery C, Candidate PharmD
出版信息
P T. 2018 Feb;43(2):85-120.
Abstract
Betrixaban (Bevyxxa): a direct-acting oral anti-coagulant factor Xa inhibitor.
摘要
贝曲西班（Bevyxxa）：一种直接作用的口服抗凝血因子Xa抑制剂。
相似文献
1
Betrixaban (Bevyxxa): A Direct-Acting Oral Anticoagulant Factor Xa Inhibitor.
P T. 2018 Feb;43(2):85-120.
2
Betrixaban: A New Oral Factor Xa Inhibitor for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients.
Ann Pharmacother. 2018 Jun;52(6):554-561. doi: 10.1177/1060028018754383. Epub 2018 Jan 17.
3
Evaluation of the oral direct factor Xa inhibitor - betrixaban.
Expert Opin Investig Drugs. 2013 Nov;22(11):1465-72. doi: 10.1517/13543784.2013.825605. Epub 2013 Aug 22.
4
Betrixaban: Impact on Routine and Specific Coagulation Assays-A Practical Laboratory Guide.
Thromb Haemost. 2018 Jul;118(7):1203-1214. doi: 10.1055/s-0038-1657772. Epub 2018 Jun 11.
5
A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT).
Thromb Haemost. 2009 Jan;101(1):68-76.
6
Betrixaban (Bevyxxa) for VTE prophylaxis in acute medical illness.
Med Lett Drugs Ther. 2018 Jan 1;60(1537):4-5.
7
The benefit of betrixaban for the extended thromboprophylaxis in acutely ill medical patients.
Expert Opin Pharmacother. 2019 Feb;20(3):261-268. doi: 10.1080/14656566.2018.1558209. Epub 2019 Jan 7.
8
Development of new methodologies for the chromogenic estimation of betrixaban concentrations in plasma.
Int J Lab Hematol. 2019 Apr;41(2):250-261. doi: 10.1111/ijlh.12963. Epub 2019 Jan 3.
9
Betrixaban - the next direct factor Xa inhibitor?
Expert Rev Hematol. 2016 Dec;9(12):1111-1117. doi: 10.1080/17474086.2016.1256194. Epub 2016 Nov 17.
10
Betrixaban: a direct oral inhibitor of activated factor X for the prophylaxis of venous thromboembolism in patients hospitalized for acute medical illness.
Drugs Today (Barc). 2017 Aug;53(8):423-434. doi: 10.1358/dot.2017.53.8.2681448.
引用本文的文献
1
Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis.
Cochrane Database Syst Rev. 2023 Apr 14;4(4):CD010956. doi: 10.1002/14651858.CD010956.pub3.
2
Potential role of IGF-1/GLP-1 signaling activation in intracerebral hemorrhage.
Curr Res Neurobiol. 2022 Sep 10;3:100055. doi: 10.1016/j.crneur.2022.100055. eCollection 2022.
3
Use of direct oral anticoagulants in ICU patients. Part I - Applied pharmacology.
Anaesthesiol Intensive Ther. 2021;53(5):429-439. doi: 10.5114/ait.2021.110607.
4
The Clinical Significance of Drug-Food Interactions of Direct Oral Anticoagulants.
Int J Mol Sci. 2021 Aug 8;22(16):8531. doi: 10.3390/ijms22168531.
5
Updates in Anticoagulation Therapy Monitoring.
Biomedicines. 2021 Mar 6;9(3):262. doi: 10.3390/biomedicines9030262.
6
Factors Affecting the Formation and Treatment of Thrombosis by Natural and Synthetic Compounds.
Int J Mol Sci. 2020 Oct 27;21(21):7975. doi: 10.3390/ijms21217975.
7
Coagulation modifiers targeting SARS-CoV-2 main protease Mpro for COVID-19 treatment: an in silico approach.
Mem Inst Oswaldo Cruz. 2020;115:e200179. doi: 10.1590/0074-02760200179. Epub 2020 Jun 1.
8
A comparative analysis of the safety profile of direct oral anticoagulants using the FDA adverse event reporting system.
Eur J Haematol. 2019 Jul;103(1):43-46. doi: 10.1111/ejh.13240. Epub 2019 May 6.
9
Safety analysis of apixaban versus warfarin in patients with advanced kidney disease.
J Thromb Thrombolysis. 2018 Aug;46(2):246-252. doi: 10.1007/s11239-018-1683-5.
本文引用的文献
1
Extended-duration versus short-duration pharmacological thromboprophylaxis in acutely Ill hospitalized medical patients: a systematic review and meta-analysis of randomized controlled trials.
J Thromb Thrombolysis. 2017 Apr;43(3):291-301. doi: 10.1007/s11239-016-1461-1.
2
Preclinical and Clinical Data for Factor Xa and "Universal" Reversal Agents.
Am J Med. 2016 Nov;129(11S):S80-S88. doi: 10.1016/j.amjmed.2016.06.009. Epub 2016 Aug 27.
3
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.
N Engl J Med. 2016 Sep 22;375(12):1131-41. doi: 10.1056/NEJMoa1607887. Epub 2016 Aug 30.
4
Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients.
N Engl J Med. 2016 Aug 11;375(6):534-44. doi: 10.1056/NEJMoa1601747. Epub 2016 May 27.
5
Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism.
Vasc Health Risk Manag. 2015 Jun 26;11:343-51. doi: 10.2147/VHRM.S63060. eCollection 2015.
6
Reversal of anticoagulants: an overview of current developments.
Thromb Haemost. 2015 May;113(5):931-42. doi: 10.1160/TH14-11-0982. Epub 2015 Apr 2.
7
Betrixaban (PRT054021): pharmacology, dose selection and clinical studies.
Future Cardiol. 2014 Jan;10(1):43-52. doi: 10.2217/fca.13.98.
8
Evaluation of the oral direct factor Xa inhibitor - betrixaban.
Expert Opin Investig Drugs. 2013 Nov;22(11):1465-72. doi: 10.1517/13543784.2013.825605. Epub 2013 Aug 22.
9
Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa).
Eur Heart J. 2013 May;34(20):1498-505. doi: 10.1093/eurheartj/eht039. Epub 2013 Mar 13.
10
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
N Engl J Med. 2013 Feb 7;368(6):513-23. doi: 10.1056/NEJMoa1111096.
Zotero 插件